Form IRANNOTICE DANAHER CORP /DE/

Go back to Form IRANNOTICE DANAHER CORP /DE/

KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report

July 21, 2022 11:40 AM EDT

KeyBanc analyst Paul Knight comments "Bioprocess market leaders Sartorius (SRT3) and Danaher (DHR) published 2Q22 results this morning with strong revenue and EPS beats, providing a positive backdrop for the industry at large. Results clearly indicate bioprocess companies are witnessing high-levels of demand, making up for the headwinds posed... More

Cowen Reiterates Outperform Rating on Danaher (DHR), 'We expect the stock to react favorably'

July 21, 2022 10:22 AM EDT

Cowen analyst Dan Brennan reiterated an Outperform rating and $343.00 price target on Danaher (NYSE: DHR).

The analyst comments "Total organic growth of 9.5% well ahead of 'LSD%' guide and our 1.8%, with organic growth ex COVID testing ('base growth') of 8.0% ahead of our 4.3%.... More

Stifel Reiterates Hold Rating on Danaher (DHR), 'we are impressed with the company's ability to perform'

July 21, 2022 10:21 AM EDT

Stifel analyst Daniel Arias reiterated a Hold rating and {REMOVEPT} price target on Danaher (NYSE: DHR).

The analyst comments "Danaher reported 2Q22 revenues of $7.75B (+7.5% y/y), which was above Stifel ($7.12B) and consensus ($7.31B). Core revenue growth of 9.5% was ahead of expectations on... More